Polymeric and lipid-based drug delivery systems for treatment of glioblastoma multiforme

Publication date: 25 November 2019Source: Journal of Industrial and Engineering Chemistry, Volume 79Author(s): Ramesh Duwa, Fakhrossadat Emami, Sooyeun Lee, Jee-Heon Jeong, Simmyung YookAbstractGlioblastoma multiforme (GBM) is the most aggressive, malignant brain tumor found in adults, and has a short median survival time (MST). GBM is a heterogeneous group of brain tumors, is highly prone to develop resistance and likely to recur. In the context of GBM, the delivery of anti-cancer drugs is challenging because the blood brain barrier (BBB) restricts the passage of small molecules. Currently, nanomedicines based on liposomes, micelles, polymeric nanoparticles, and microparticles have attracted much attention, because they can cross the BBB and deliver anti-cancer drugs specifically to brain tumors. In this context, hydrogel-based systems incorporating nanoparticles, implantable carmustine wafers, microspheres, and lipid-based nanoparticles now appear to offer more effective, safer treatment strategies than conventional chemotherapeutic regimens. This review describes different polymeric hydrogel, chitosan, dendrimers, wafers, microspheres, and lipid-based nanoparticles like liposomes and solid-lipid nanoparticles that offers prominent strategies for the treatment and diagnosis of GBM.Graphical abstract
Source: Journal of Industrial and Engineering Chemistry - Category: Chemistry Source Type: research

Related Links:

Nature, Published online: 14 October 2019; doi:10.1038/d41586-019-03042-0The body’s circadian clock ensures the rhythmic expression of some genes across the day. The catalogue of genes under circadian control changes in an aggressive brain cancer — a discovery that might open up a new avenue for treatment.
Source: Nature AOP - Category: Research Authors: Source Type: research
In conclusion, we performed the largest study so far focused on CSF miRNA profiling in patients with brain tumors, and we believe that this new class of biomarkers have a strong potential as a diagnostic and prognostic tool in these patients.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Our weekly round-up of the best psychology coverage from elsewhere on the web There’s not much evidence that brain training apps really improve our cognitive abilities –  so why do so many people use them? Sabrina Weiss at Wired has the answers. More colour-related research this week: people who live in grey, rainy countries far away from the equator are more likely to associate yellow with joy, reports Eva Frederick in Science. Most people in Finland, for instance, felt that yellow was related to the feeling of joy, while very few of those in countries like Egypt and Saudi Arabia made that associat...
Source: BPS RESEARCH DIGEST - Category: Psychiatry & Psychology Authors: Tags: Weekly links Source Type: blogs
Researchers have recently published 'the first demonstration' that a promising blood test for detecting brain cancer works in the clinic.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Head and Neck Cancer Source Type: news
o Monica Fedele Glial tumors are the leading cause of cancer-related death and morbidity in children. Their diagnosis, mainly based on clinical and histopathological factors, is particularly challenging because of their high molecular heterogeneity. Thus, tumors with identical histotypes could result in variable biological behaviors and prognoses. The PATZ1 gene has been recently shown to be expressed in adult gliomas, including glioblastomas, where it correlates with the proneural subtype and with a better prognosis. Here, we analyzed the expression of PATZ1 in pediatric gliomas, first at mRNA level in a public data...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Researchers from the University of Strathclyde have developed a blood test that could help to accelerate the diagnosis of brain cancer. The technology uses infrared light to produce a "bio-signature" of a blood sample and applies artificial intelligence to check for the signs of cancer. This research is being commercialized by ClinSpec Diagnostics Ltd, a company spun out from the university in February 2019. The work has now been published in the journal Nature Communications, and also involved clinicians at the Western General Hospital in Edinburgh, the University of Liverpool and the Walton NHS Foundation Trust...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Digital Health Source Type: news
Purpose of review The current review summarizes recent advances on three important issues in neurofibromatosis type 1 (NF1) management: the identification of specific NF1 gene mutations predicting the risk for developing neurological malignancies; the molecular features of NF1-associated tumors and their differences from sporadic neoplasms; genetic, epigenetic, or microenviromental factors leading benign tumors to a malignant transformation in NF1. Recent findings The association between the risk of developing optic pathway glioma and specific germiline NF1 mutations is still debated and further studies are needed wit...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: BRAIN AND NERVOUS SYSTEM: Edited by Marc Sanson Source Type: research
Abstract Significant progress on circulating tumor cells (CTCs) has profound impact for noninvasive tumor profiling including early diagnosis, treatment monitoring, and metastasis recognition. Therefore, CTCs based liquid biopsy technology is taking a rapid growth in the field of precision oncology. The label-free approaches relied on microfluidic chip stand out from a crowd of methods that suffer from time consuming, extensive blood samples, lost target cells and labor-intensive operation. In this paper, a label-free separation microfluidic device was developed using multistage channel, which took full advantage ...
Source: Talanta - Category: Chemistry Authors: Tags: Talanta Source Type: research
CONCLUSION: In osteosarcoma, lncRNA TTN-AS1 promoted the expression of MBTD1 by targeting miR-134-5p and regulated cell growth, apoptosis and drug resistance. METHODS: The expression characteristics of genes in osteosarcoma patients were analysed using bioinformatics. Plasmid transfection technology was applied to silence or overexpress lncRNA TTN-AS1, miR-134-5p and MBTD1. Western blotting and quantitative polymerase chain reaction (qPCR) were used to detect protein and RNA, respectively. A cell counting kit 8 (CCK-8) and flow cytometry were used to detect cell viability and apoptosis. The effects of lncRNA TTN-AS1 a...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
PMID: 31600806 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Tags: Thromb Haemost Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Chemistry | Nanotechnology | Neurology